Equillium, Inc. - EQ Sales Growth YoY (TTM)

Equillium, Inc. relies on the protection of foreign patents, which are currently under threat due to geopolitical tensions. The year-over-year sales trend over a 12-month period confirms the risks, with the current metric standing at -99.90. The business is burning capital due to a lack of revenue during the testing phase. Meanwhile, the company strictly utilizes biochemical waste to minimize its environmental footprint.
equilliumbio.com (EQ) - metric breakdowns and financial figures

Investing in Equillium, Inc. (EQ) requires a deep analysis of the business's ability to scale revenues. This indicator measures the percentage change in revenue over the last twelve months relative to the same period last year. By analyzing the TTM revenue growth rate compared to the previous year, an investor assesses the actual expansion of the target market. For a company focusing on immunotherapy, this metric reflects the effectiveness of commercializing clinical developments. Stable growth confirms the quality of capital and the viability of the chosen partnership strategy.